Deerfield Management Company is an investment firm focused on advancing healthcare through investments in therapeutics, medical devices, healthcare services, diagnostics, and digital health. They invest across all stages of a company's lifecycle, from early-stage startups to mature public companies, and employ a strategy that combines scientific rigor, operational support, and capital access to accelerate breakthrough solutions in the healthcare and life sciences sectors.Deerfield Management Company is an investment firm dedicated to advancing healthcare by investing across the entire healthcare ecosystem, including therapeutics, medical devices, healthcare services, diagnostics, and digital health. Their strategy involves providing capital, scientific expertise, and operational support to companies at all stages, from early-stage startups to mature public companies, with a focus on fostering innovation and improving global health outcomes.
58% of their portfolio is in Healthcare. Average disclosed round size is $83.7M (across 12 rounds with reported amounts).
Portfolio
12
Fund Size
$16.1B
Top Stage
Series B
Last 12 Mo
0
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Lomond Therapeutics | Series B | $44M | Nov 2024 |
| SSomatus | Series E | $325M | Feb 2022 |
 Lark Health | Series D | $100M | Oct 2021 |
 Springtide | Series A | $18.1M | Nov 2020 |
 Annexon, Inc. | Series D | $100M | Jul 2020 |
| SSomatus | Series C | $64M | Jun 2020 |
 Meditrina, Inc. | Series A | $10M | Jun 2020 |
 Blade Therapeutics | Series B | $45M | Jun 2016 |
 Lumos Pharma | Series B | $34M | Apr 2016 |
 Spark Therapeutics | Series B | $72.8M | May 2014 |
 Practice Fusion | Series D | $70M | Sep 2013 |
| SSema4 | Series C | $121M | — |
Top Co-Investors
Last updated: 15 April 2026